Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: An Australian population-based study 1998 to 2008

Transfusion

Volumn 53, Issue 8, 2013, Pages 1714-1721

  McQuilten, Zoe K ^b   Polizzotto, Mark N ^a   Wood, Erica M ^a   Sundararajan, Vijaya ^a  

^a not available   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; AUSTRALIA; BLOOD TRANSFUSION REACTION; CANCER REGISTRY; CAUSE OF DEATH; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; EVENT FREE SURVIVAL; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INCIDENCE; IRON OVERLOAD; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LEUKEMIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; MYELODYSPLASTIC SYNDROME; POPULATION RESEARCH; RETROSPECTIVE STUDY; SEPSIS; THROMBOCYTE TRANSFUSION;

EID: 84882455895     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12054     Document Type: Article

References (31)

1. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF,. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112: 45-52.
2. Ma X, Does M, Raza A, Mayne ST,. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007; 109: 1536-1542.
3. Australian Institute of Health and Welfare (AIHW). ACIM (Australian Cancer Incidence and Mortality) books. Canberra: AIHW; 2010.
4. Cogle CR, Craig BM, Rollison DE, List AF,. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011; 117: 7121-7125.
5. Cogle CR, Cole A, Imanirad I, Kamat L, Yu D, List A, Rollison DE,. A keyword search strategy to identify missed cases of myelodysplastic syndromes in population-based cancer registries. ASH Annu Meet Abstr 2009; 114: 4852.
6. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, Laouri M,. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010; 28: 2847-2852.
7. Nachtkamp K, Kundgen A, Strupp C, Giagounidis A, Kobbe G, Gattermann N, Haas R, Germing U,. Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 2009; 33: 1024-1028.
8. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR,; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
9. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R,; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
10. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF,. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86-93.
11. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M,. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603.
12. Chee CE, Steensma DP, Wu W, Hanson CA, Tefferi A,. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008; 83: 611-613.
13. Tefferi A, Stone RM,. Iron chelation therapy in myelodysplastic syndrome-cui bono? Leukemia 2009; 23: 1373.
14. Ramsey SD, McCune JS, Blough DK, McDermott CL, Beck SJ, Lõpez JA, Deeg HJ,. Patterns of blood product use among patients with myelodysplastic syndrome. Vox Sang 2012; 102: 331-337.
15. Australian Institute of Health and Welfare (AIHW). Cancer in Australia: an overview, 2008. Cat. no. CAN 42. Canberra: AIHW. 2008. [cited 2012 Jul 1]. Available from: URL: http://www.aihw.gov.au/publication-detail/?id=6442468196
16. Australian Bureau of Statistics. 3218.0. Regional population growth, Australia, 2009-10. Canberra, Australian Bureau of Statistics, 2011. [cited 2012 Jul 1]. Available from: URL: http://www.abs.gov.au/ausstats/abs.nsf/Products/ 3218.0~2009-10~Main+Features~Main+Features?OpenDocument
17. Australian Bureau of Statistics. Private health insurance: a snapshot, 2004-05. Canberra, Australian Bureau of Statistics, 2006. [cited 2012 Jul 1]. Available from: URL: http://www.abs.gov.au/ausstats/abs.nsf/mf/4815.0.55.001
18. National Centre for Classification in Health (Sydney). The international statistical classification of diseases and related health problems, tenth revision, Australian modification. 5th ed. Sydney, Australia: National Centre for Classification in Health, Faculty of Health Sciences, The University of Sydney; 2006.
19. National Centre for Classification in Health (Sydney). The Australian classification of health interventions (ACHI). 5th ed. Sydney, Australia: National Centre for Classification in Health, Faculty of Health Sciences, The University of Sydney; 2006.
20. Henderson T, Shepheard J, Sundararajan V,. Quality of diagnosis and procedure coding in ICD-10 administrative data. Med Care 2006; 44: 1011-1019.
21. Delea TE, Hagiwara M, Phatak PD,. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 2009; 25: 139-147.
22. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M,. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510.
23. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA,. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139.
24. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA,. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004; 57: 1288-1294.
25. Gardner W, Mulvey EP, Shaw EC,. Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. Psychol Bull 1995; 118: 392-404.
26. NationMaster. United States age distribution. [cited 2012 Jul 1]. Available from: URL: http://www.nationmaster.com/country/us-united-states/Age- distribution
27. Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA,. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res 1999; 23: 953-959.
28. Wang R, Gross CP, Halene S, Ma X,. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 2009; 33: 1594-1598.
29. Bullen JJ, Rogers HJ, Spalding PB, Ward CG,. Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol 2006; 55 (Pt 3): 251-258.
30. Pullarkat V,. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 2009; 114: 5251-5255.
31. Sundararajan V, Macisaac CM, Presneill JJ, Cade JF, Visvanathan K,. Epidemiology of sepsis in Victoria, Australia. Crit Care Med 2005; 33: 71-80.